List of Excipients in Branded Drug DYE FREE IBUPROFEN

« Back to Dashboard

Generic Drugs Containing DYE FREE IBUPROFEN

Company	Ingredient	NDC	Excipient
Walgreen Company	ibuprofen	0363-0438	ANHYDROUS LACTOSE
Walgreen Company	ibuprofen	0363-0438	CELLULOSE, MICROCRYSTALLINE
Walgreen Company	ibuprofen	0363-0438	HYPROMELLOSE
Walgreen Company	ibuprofen	0363-0438	MAGNESIUM STEARATE
Walgreen Company	ibuprofen	0363-0438	POLYDEXTROSE

What are the Most Frequently-Used Excipients in DYE FREE IBUPROFEN?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
3	CELLULOSE, MICROCRYSTALLINE
3	HYPROMELLOSE
3	MAGNESIUM STEARATE
3	POLYDEXTROSE

Dye-Free Ibuprofen Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Dye-free ibuprofen is a formulation and branding opportunity rather than a new-molecule opportunity. Ibuprofen has no meaningful remaining active-ingredient exclusivity in the United States, and most OTC products can be marketed under the FDA analgesic monograph if they satisfy the applicable conditions. Commercial value comes from excipient selection, pediatric usability, allergen avoidance, clean-label positioning, dosage-form innovation, and retailer-specific differentiation.

What is the FDA regulatory status of dye-free ibuprofen?

Dye-free ibuprofen is not a separate active pharmaceutical ingredient or FDA-defined drug category. It is ibuprofen marketed without selected color additives, typically FD&C dyes.

Oral ibuprofen products may be marketed under the FDA OTC monograph for internal analgesic, antipyretic, and antirheumatic drug products, subject to the monograph’s active-ingredient, dosage, labeling, and testing requirements. The governing framework is 21 C.F.R. Part 343 and the FDA’s OTC monograph system. A dye-free product remains an ibuprofen product; removing a colorant does not create a new regulatory pathway.

Regulatory issue	Commercial impact
Active ingredient	Ibuprofen, usually 200 mg in adult OTC tablets or capsules
Pediatric liquid strength	Commonly 100 mg/5 mL
FDA pathway	OTC monograph or, for certain approved products, an NDA
Colorants	Not required for efficacy; may be removed if appearance and stability remain acceptable
Orange Book status	Usually not applicable to monograph-marketed OTC products
Paragraph IV	Relevant to an ANDA or patent-listed NDA, not normally to a monograph product
Biosimilar pathway	Not applicable; ibuprofen is a chemically synthesized small molecule
Core labeling	Drug Facts labeling under FDA requirements

A company should not describe a product as “free of dyes” if the formulation contains another color additive, such as titanium dioxide or iron oxides, unless the claim is narrowly defined and supported by the product’s ingredient disclosure. “Dye-free” and “colorant-free” are not equivalent claims.

What excipients are most suitable for dye-free ibuprofen tablets?

The most practical tablet strategy is an uncoated or minimally coated white-to-off-white tablet using standard direct-compression or wet-granulation excipients.

Recommended tablet excipient architecture

Formulation function	Candidate excipients	Strategic rationale
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Supports tablet weight, flow, and mechanical strength
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Controls breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Film coating	Hypromellose, polyethylene glycol, talc	Provides swallowability and handling protection
Opacifier or pigment	Avoid where a strict colorant-free claim is intended	Preserves claim simplicity

Ibuprofen is a hydrophobic, poorly water-soluble drug. Excessive hydrophobic lubricant, especially magnesium stearate, can slow wetting and dissolution. Lubricant concentration and blending time should be controlled during development. Crospovidone or croscarmellose sodium can offset slow wetting, but the final system requires dissolution testing across relevant pH conditions.

An uncoated tablet provides the clearest dye-free value proposition. It also reduces coating complexity, lowers manufacturing cost, and avoids disputes over whether a coating pigment is consistent with “clean-label” positioning. The tradeoff is greater exposure to odor, moisture, abrasion, and visual variability.

What excipients are suitable for dye-free pediatric ibuprofen suspensions?

Pediatric liquid ibuprofen offers the strongest formulation opportunity because caregivers actively evaluate dyes, sugar, alcohol, preservatives, and flavor systems.

Ibuprofen has low intrinsic water solubility. A conventional pediatric liquid is therefore usually a suspension rather than a true aqueous solution. The formulation must maintain uniform drug distribution during storage and allow rapid redispersion after shaking.

Candidate pediatric suspension system

Function	Candidate excipients	Key development issue
Vehicle	Purified water, glycerin, sorbitol	Palatability, viscosity, osmotic load
Suspending agent	Xanthan gum, microcrystalline cellulose with carboxymethylcellulose, hydroxyethylcellulose	Sedimentation and redispersion
Wetting agent	Polysorbate 80 or equivalent	Reduces ibuprofen wetting problems
Buffer or pH modifier	Citric acid, sodium citrate, phosphate system	Stability, taste, preservative performance
Preservative	Sodium benzoate, potassium sorbate, or another suitable system	Microbial control and pH dependence
Sweetener	Sucralose, saccharin sodium, sorbitol	Taste masking without sucrose
Flavor	Natural or artificial fruit flavor	Must be compatible with the dye-free claim
Antifoam	Simethicone or formulation-specific alternative	Useful where shaking creates persistent foam

A sugar-free and dye-free product can command a stronger premium than a dye-free tablet because it addresses several pediatric purchase criteria at once. The formulation must also avoid alcohol where pediatric positioning requires an alcohol-free claim.

The main technical risks are caking, dose nonuniformity, sedimentation, preservative failure, flavor instability, and inaccurate dosing caused by inadequate oral syringes. A calibrated dosing syringe is a low-cost commercial differentiator and can reduce administration errors compared with a household spoon.

What formulations are protected by patents?

Dye-free ibuprofen generally has a weak patent position at the active-ingredient level. Ibuprofen’s original composition-of-matter and early pharmaceutical patents expired long ago. A modern product may still have protection for a specific formulation, delivery system, manufacturing process, or combination, but those rights are product-specific.

Patent categories relevant to dye-free ibuprofen

Patent category	Potential scope	Commercial relevance
Composition of matter	Ibuprofen molecule or salt	No meaningful current barrier for ordinary ibuprofen
Solid dosage formulation	Excipients, dissolution profile, tablet architecture	Usually narrow and design-aroundable
Liquid suspension	Suspending system, particle size, rheology, preservative system	More relevant for pediatric products
Taste masking	Coated particles, complexes, granules, flavor system	Can protect premium pediatric products
Delivery system	Chewable, orally disintegrating, softgel, liquid-filled capsule	May support product differentiation
Manufacturing process	Milling, granulation, coating, or encapsulation process	Can create operational barriers
Method of use	Dosing regimen or indication	Narrow value for a widely used OTC analgesic
Packaging	Unit-dose, child-resistant, dosing-device integration	Usually protection is limited and commercially secondary

A company should not assume that a formulation patent prevents all competing dye-free products. Patent scope depends on the claims, product composition, prosecution history, and whether the formulation is listed for an approved NDA. A dye-free label alone is unlikely to support a broad enforceable patent claim.

When does ibuprofen lose exclusivity?

Ibuprofen lost practical U.S. molecule-level exclusivity decades ago. The product is widely available from branded and generic manufacturers, including private-label retailers.

Exclusivity type	Current position
New chemical entity exclusivity	Expired
Basic active-ingredient patent	Expired
OTC monograph access	Available subject to compliance
Generic competition	Extensive
Formulation exclusivity	Possible only for a specific approved product or patent claim
Pediatric exclusivity	No general category-wide exclusivity
Biosimilar exclusivity	Not applicable

The commercial launch risk is therefore not blocked by ibuprofen exclusivity. The relevant questions are compliance with the monograph, manufacturing economics, retailer acceptance, quality performance, and consumer differentiation.

What is the Orange Book status of dye-free ibuprofen?

Most monograph-marketed dye-free ibuprofen products will not have an Orange Book patent listing because the Orange Book primarily identifies approved drug products and patent or exclusivity information associated with approved NDAs and certain related applications.

An NDA-approved ibuprofen product may have Orange Book entries, but that status cannot be assigned to the entire dye-free category. A private-label or monograph product should not be described as Orange Book-listed without confirming the specific application number and product record.

Paragraph IV and generic launch implications

Paragraph IV litigation becomes relevant if a company files an ANDA referencing an NDA with listed patents and certifies that the patents are invalid, unenforceable, or not infringed. It is not the normal route for launching a conventional ibuprofen product under the OTC monograph.

For a standard dye-free tablet or suspension, the more likely launch model is:

1. Select an OTC-monograph-compliant ibuprofen strength and dosage form.
2. Qualify active and inactive ingredients.
3. Establish stability, dissolution, microbial, and content-uniformity performance.
4. Implement Drug Facts labeling.
5. Register and list the product as required.
6. Launch through a brand, private-label, or retailer program.

How strong is the patent estate for dye-free ibuprofen?

The patent estate is weak for basic products and potentially moderate for technically differentiated pediatric systems.

Product concept	Patent strength	Likely commercial barrier
Uncoated 200 mg dye-free tablet	Low	Manufacturing scale and retailer access
Dye-free softgel	Low to moderate	Capsule technology and supplier economics
Sugar-free pediatric suspension	Moderate	Taste, stability, rheology, and preservative know-how
Dye-free orally disintegrating tablet	Moderate	Taste masking and mechanical performance
Long-acting ibuprofen system	Moderate to high if clinically differentiated	Regulatory and clinical requirements
Unit-dose pediatric syringe system	Low to moderate	Packaging execution and channel contracts
Proprietary particle-engineered suspension	Moderate	Process control and formulation patents

The strongest defensible position is likely to come from a combined package of know-how, trademarks, formulation patents, manufacturing controls, and retailer exclusivity. A single “dye-free” claim is easy to copy.

What commercial opportunities exist for dye-free ibuprofen?

Pediatric OTC products

Pediatric suspension is the clearest opportunity. Caregivers commonly look for products that are dye-free, sugar-free, alcohol-free, and easy to dose. A product combining these attributes can occupy a premium segment without changing the active ingredient.

The most attractive specifications are:

• 100 mg/5 mL strength
• Dye-free and sugar-free formulation
• Alcohol-free positioning
• Clear Drug Facts dosing tables
• Oral syringe included
• Berry, grape, or fruit flavor without visible color
• Low-foam suspension with rapid redispersion
• Child-resistant packaging
• Small bottle sizes for occasional household use

Adult tablets and caplets

Adult dye-free tablets have a lower technical barrier and higher price pressure. The opportunity is strongest in:

• Hypoallergenic or excipient-minimized products
• Pharmacy and hospital channels
• Private-label retailer programs
• E-commerce search categories
• Combination bundles with acetaminophen-free positioning
• Products targeting consumers who avoid artificial colors

A simple white tablet may be commercially sufficient. Premium pricing requires a stronger claim, such as dye-free plus gluten-free, lactose-free, vegan, or minimal-excipient positioning, provided each claim is substantiated.

Softgels and liquid-filled capsules

Softgels can differentiate on swallowability and rapid disintegration. The main barriers are gelatin or plant-based shell selection, colorant avoidance in the shell, oxygen and moisture protection, and higher unit cost.

A plant-based capsule may appeal to vegan consumers but can create a different technical profile involving shell brittleness, moisture sensitivity, and slower scale-up. The claim architecture must distinguish “dye-free” from “gelatin-free” and “vegan.”

Institutional and hospital supply

Hospitals and health systems may prefer products with fewer colorants, simpler excipient profiles, and reliable supply. Institutional opportunities include:

• Unit-dose tablets
• Blister packaging
• Pediatric oral syringes
• Automated dispensing cabinet compatibility
• Products with clear allergen and excipient declarations

Hospital purchasing is price-sensitive. Supply continuity, quality documentation, and contract reliability usually matter more than consumer premium branding.

How does dye-free ibuprofen compare with competing analgesics?

Product	Dye-free opportunity	Formulation complexity	Competitive intensity
Ibuprofen	Strong in pediatric suspension and clean-label products	Moderate	High
Acetaminophen	Strong pediatric and infant positioning	Moderate	Very high
Naproxen sodium	Adult extended-duration positioning	Low to moderate	Moderate
Aspirin	Limited pediatric opportunity because of safety restrictions	Low	Moderate
Topical NSAIDs	Delivery-system differentiation	High	Moderate to high

Ibuprofen competes directly with acetaminophen in pediatric care. The differentiation is not usually a superior efficacy claim. It is ease of dosing, taste, excipient profile, product availability, and consumer trust.

What manufacturing and intellectual-property barriers exist?

The most important barriers are operational rather than molecule-based.

Manufacturing barriers

• Uniform suspension dosing at commercial scale
• Consistent particle-size distribution
• Adequate wetting of hydrophobic ibuprofen
• Preservation across the product shelf life
• Flavor masking without colorants
• Tablet dissolution despite lubricant use
• Control of polymorphic or particle-size variation
• Stability of packaging and dosing components
• Supplier qualification for specialized excipients

Intellectual-property barriers

• Suspension rheology systems
• Taste-masked ibuprofen particles
• Orally disintegrating dosage forms
• Rapid-release or fast-acting claims
• Softgel shell systems
• Unit-dose packaging and integrated dosing devices
• Process patents covering particle engineering

A development program should conduct a freedom-to-operate review against identified competitor products rather than relying on a category-level search. The main risk is infringement of a narrow formulation or process claim, not infringement of the ibuprofen molecule.

Which companies are challenging the dye-free ibuprofen market?

Competition is fragmented across branded OTC manufacturers, generic companies, contract manufacturers, and retailer-owned labels. Representative competitive groups include:

• Major branded analgesic companies
• Generic manufacturers supplying pharmacy and mass-market channels
• Retailers selling private-label ibuprofen
• Pediatric-focused OTC brands
• E-commerce brands emphasizing clean-label excipients
• Contract development and manufacturing organizations

Retailer private labels can compress pricing quickly. A branded entrant needs either a proprietary pediatric experience, strong distribution, a trusted brand, or a measurable formulation advantage.

What licensing deals and partnership models are available?

The most practical licensing targets are formulation and manufacturing technologies rather than ibuprofen rights.

Potential deal structures include:

Partnership model	Asset contributed	Best use
CDMO license	Suspension, softgel, or tablet platform	Rapid market entry
Retailer private label	Formulation plus supply agreement	Volume-driven launch
Pediatric brand license	Brand, flavor, packaging, and distribution	Premium consumer positioning
Device partnership	Oral syringe or unit-dose dispenser	Dosing differentiation
Ingredient supplier agreement	Suspending, taste-masking, or wetting technology	Technical performance
Regional license	Product rights by country or territory	Geographic expansion

A supply agreement with minimum purchase commitments may create more value than a narrow formulation patent. Retailer exclusivity can provide short-term market protection, but it can also limit channel expansion and weaken brand-building.

What geographic coverage is available?

The United States is favorable for dye-free OTC ibuprofen because the active ingredient is established and monograph access reduces dependence on a product-specific NDA. International launch requirements vary.

The European Union, United Kingdom, Canada, Australia, and other markets may differ in:

• Permitted color additives
• Titanium dioxide treatment
• Preservative limits
• Pediatric labeling
• Ibuprofen dose limits
• Medical-device requirements for dosing syringes
• National product authorization pathways
• Rules governing traditional or OTC medicines

A U.S. “dye-free” formulation may need reformulation for Europe if it uses colorants, preservatives, sweeteners, or excipients treated differently under local rules. Global development should start with a conservative excipient panel that avoids unnecessary pigments and minimizes region-specific ingredients.

What generic launch scenarios exist?

Scenario 1: Low-cost adult tablet

A manufacturer launches an uncoated 200 mg tablet under the OTC monograph. This is the lowest-risk and lowest-margin option. Success depends on cost, supply reliability, retailer access, and packaging.

Scenario 2: Premium pediatric suspension

A company launches a dye-free, sugar-free, alcohol-free 100 mg/5 mL suspension with an oral syringe. This has higher formulation complexity and stronger consumer differentiation.

Scenario 3: Retailer-exclusive product

A private-label retailer receives an exclusive formulation and packaging configuration. Volume can be substantial, but the supplier may lose consumer brand equity.

Scenario 4: Specialty clean-label brand

A company positions ibuprofen for consumers seeking minimal excipients and transparent labeling. This can support premium pricing but requires strong substantiation and disciplined claims management.

Scenario 5: Technology-led dosage form

An orally disintegrating, softgel, or taste-masked product supports a more defensible formulation position. Development time, manufacturing cost, and regulatory review are higher.

Key Takeaways

• Dye-free ibuprofen is a formulation and commercial segmentation opportunity, not a molecule-exclusivity opportunity.
• Pediatric suspension is the strongest target because dye-free, sugar-free, alcohol-free, and dosing-device attributes can be combined.
• Adult dye-free tablets are easy to develop but face intense price and private-label competition.
• The Orange Book and Paragraph IV framework usually do not control a conventional monograph-marketed ibuprofen launch.
• Patent strength is low for a basic uncoated tablet and higher for proprietary suspensions, taste masking, particle engineering, or advanced dosage forms.
• The best defensible position combines formulation know-how, process control, branding, packaging, retailer access, and supply reliability.
• A global product should avoid unnecessary pigments and use an excipient platform that can meet differing regional rules.
• Commercial returns are likely to come from channel access and premium pediatric positioning rather than from patent exclusivity.

FAQs

Is dye-free ibuprofen safer than regular ibuprofen?

Dye-free ibuprofen removes selected colorants but does not change ibuprofen’s NSAID pharmacology, contraindications, or gastrointestinal, renal, and cardiovascular risk profile.

Can dye-free ibuprofen be marketed without an NDA?

A qualifying OTC product may be marketed under the applicable FDA OTC monograph. Product-specific regulatory obligations still apply, including manufacturing, labeling, registration, listing, and quality requirements.

Is titanium dioxide allowed in a dye-free ibuprofen product?

Titanium dioxide is distinct from FD&C dyes but is a color additive. A product marketed as “dye-free” may technically exclude FD&C dyes while containing titanium dioxide, but a stricter “colorant-free” or clean-label strategy should avoid it.

What is the most defensible dye-free ibuprofen product?

A pediatric suspension with proprietary taste masking, strong redispersion performance, an integrated dosing syringe, and a differentiated excipient profile is more defensible than a standard white tablet.

Does dye-free ibuprofen have biosimilar competition?

No. Biosimilars apply to biological products. Ibuprofen is a chemically synthesized small molecule and competes through generic, OTC-monograph, private-label, and branded products.

References

1. U.S. Food and Drug Administration. (2023). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.accessdata.fda.gov

2. U.S. Food and Drug Administration. (2024). Drug facts labeling for nonprescription drugs. https://www.fda.gov/drugs/understanding-over-counter-medicines/over-counter-drug-facts-label

3. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.